Gentium S.p.A. Receives Positive Opinion From European Medicines Agency's CHMP for Defitelio

Published: Jul 26, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

VILLA GUARDIA, Italy, July 26, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that, following its request for re-examination, the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP") adopted a positive opinion for Defitelio recommending a Marketing Authorization Application ("MAA") under exceptional circumstances, for the treatment of severe hepatic veno-occlusive disease ("VOD") in adults and children undergoing hematopoietic stem cell transplantation therapy.

Help employers find you! Check out all the jobs and post your resume.

Back to news